Topical Retinoids & Acid Actives — Resident Study Notes
Retinoid Generations & RAR Selectivity
| Generation | Examples | RAR selectivity | Indications |
|---|---|---|---|
| 1st gen | Tretinoin (all-trans-RA), Isotretinoin, Alitretinoin | Pan-RAR (α/β/γ) | Acne, photoaging, AK; FDA tretinoin since 1971 |
| 2nd gen | Etretinate, Acitretin (oral) | Pan-RAR | Psoriasis, ichthyosis |
| 3rd gen | Adapalene, Tazarotene, Bexarotene | Adapalene RAR-β/γ; Tazarotene RAR-β/γ | Photostable; less irritation; better daytime tolerance |
| 4th gen | Trifarotene | Highly selective RAR-γ | Acne (truncal); minimal RAR-α off-target → less systemic risk |
Retinoid Conversion Pathway & Relative Potency
Retinyl ester (cosmetic) → Retinol → Retinaldehyde → Retinoic acid (active). Each conversion step is rate-limiting and reduces potency by ~10-20×:
- Retinyl palmitate / acetate: very weak (1×)
- Retinol: ~ 20× weaker than tretinoin; OTC standard
- Retinaldehyde: ~ 5-10× weaker than tretinoin; faster onset than retinol
- Tretinoin: gold standard; full potency
- Tazarotene 0.1%: ≈ Tretinoin 0.05% (slightly more potent and irritating)
Bakuchiol — "Plant-Based Retinol Alternative"
Meroterpene phenol from Psoralea corylifolia. Activates retinoid-like gene expression without binding RAR directly. Dhaliwal et al. 2019 RCT: 0.5% bakuchiol BID = 0.5% retinol BID for photoaging at 12 weeks, with less irritation. Safe in pregnancy (limited data). Not as well-studied as retinoids overall.
Hydroxy Acids: AHA / BHA / PHA
| Class | Examples | Molecule size / pKa | Penetration | Best use |
|---|---|---|---|---|
| AHA (water-soluble) | Glycolic (pKa 3.83), Lactic (3.86), Mandelic (3.41) | Small (glycolic 76 Da) | Epidermis surface | Brightening, fine texture |
| BHA (oil-soluble) | Salicylic (pKa 2.97) | 138 Da, lipophilic | Penetrates pores (oil-soluble) | Acne, blackheads, seborrhea |
| PHA | Gluconolactone, Lactobionic acid | Larger | Slower penetration | Sensitive skin; gentle exfoliation |
Free acid % depends on pH: only the protonated (free acid) form penetrates well. At pH = pKa, 50% is free acid. Most products formulate at pH 3.5-4 to optimize free acid % while limiting irritation.
Azelaic Acid — Dual Mechanism
- Tyrosinase inhibitor → anti-pigmentation (melasma, PIH)
- Antimicrobial (against C. acnes) + anti-inflammatory → acne, rosacea
- Selective effect on hyperactive melanocytes — doesn't affect normal pigmentation
- Concentrations: 15% gel (rosacea), 20% cream (acne); pregnancy Category B
Compatibility & Stacking
- Tretinoin + BPO: Tretinoin oxidatively degraded by BPO → use at different times (morning BPO, night tretinoin) OR use stable formulations (Microsphere tretinoin, Adapalene)
- Adapalene + BPO: chemically stable → fixed-combo Epiduo / Acnatac approved for same-time use
- Vitamin C (L-AA) + Retinoid: pH conflict (L-AA pH 3.5, retinoid pH 5-6); separate timing or 30-min wait
- Niacinamide + L-AA: long-debated; modern data shows compatible at moderate concentrations
- Multi-acid layering: skip; pick one acid family + one antioxidant
Pregnancy Safety
- Avoid: oral retinoids (Cat X), topical tretinoin / tazarotene (Cat C-X — limited absorption but theoretical risk), high-strength salicylic acid (> 2%)
- Acceptable: azelaic acid (B), benzoyl peroxide (C — limited absorption), glycolic acid (limited safety data; small superficial use likely OK), niacinamide, vitamin C
- FDA's PLLR (2015) replaced letter categories with detailed pregnancy / lactation summaries
Retinoid Dermatitis Management
- Cause: too high concentration, too frequent, with irritating actives
- Acute: stop retinoid 2-7 days, mid-strength TCS BID × 5-7 days, gentle moisturizer
- Re-introduce: every-third-night, "buffer" with moisturizer applied first
- Switch to gentler retinoid (Adapalene 0.1%, retinaldehyde) if persistent intolerance
AAD 2024 + NICE NG198 — Topical Therapy Synthesis
AAD 2024 (Reynolds et al., JAAD 2024;90:1006)
- Strong rec: BPO; topical retinoid (tretinoin / adapalene / tazarotene / trifarotene); topical clindamycin; fixed-dose combinations of BPO+retinoid, BPO+clindamycin, retinoid+clindamycin, and triple BPO+retinoid+clindamycin.
- Conditional rec: clascoterone 1% BID (Winlevi) — first topical androgen-receptor inhibitor, both sexes; salicylic acid; azelaic acid; topical minocycline 4% foam (Amzeeq); dapsone 5% / 7.5% gel.
- Best-practice: combine multi-mechanism topicals; avoid topical antibiotic monotherapy; pair systemic antibiotics with topicals; intralesional triamcinolone for nodules.
- Trifarotene 50 µg/g — first FDA-approved retinoid for truncal acne (RAR-γ selective).
NICE NG198 (2021, updated April 2026)
- 12-week first-line options (1.5.1): adapalene+BPO; tretinoin+clindamycin; BPO+clindamycin (mild-mod only); adapalene+BPO + oral lymecycline / doxycycline (mod-severe); azelaic acid + oral lymecycline / doxycycline (mod-severe).
- BPO monotherapy as alternative; topical antibiotic monotherapy not recommended.
- Topical retinoid avoidance in pregnancy; azelaic acid acceptable.
- Tetracyclines: limit to ≤ 12-16 weeks; sarecycline (Seysara, narrow-spectrum, AAD conditional rec) is an alternative with less GI dysbiosis.
References
- Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-e30. doi:10.1016/j.jaad.2023.12.017 [Source]
- National Institute for Health and Care Excellence. Acne vulgaris: management (NG198). London: NICE; 2021 (last updated April 2026). [Source]
- Tan J, et al. Trifarotene 50 µg/g cream for moderate facial and truncal acne. JAAD. 2019;80(6):1691-1699.
- Hebert A, et al. Clascoterone cream 1% — phase 3 RCTs. JAMA Dermatol. 2020;156(6):621-630.
- Moore A, et al. Sarecycline 1.5 mg/kg/day for moderate-to-severe acne — phase 3. J Drugs Dermatol. 2018;17(9):987-996.
Patient handout: see Topical Acids Patient Guide for plain-language version.